The announcement of the registered direct offering and concurrent private placement may have mixed effects on Microbot Medical's stock price. On one hand, it could be seen as a positive sign of the company raising capital for growth. On the other hand, the dilution of shares may lead to a short-term negative impact on the stock price. Overall, the impact is expected to be neutral in the short term.